- ￥1080 - 17000
- Prospecbio
- 以色列
- chm-243
- 2025年12月28日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
for future use below -18°C
- 保质期：
See instructions
- 英文名：
PF4 Variant-1
- 库存：
常规产品有备货
- 供应商：
上海经科化学科技有限公司
- CAS号：
无
- 规格：
1ug/5ug/50ug
| 规格： | 1ug | 产品价格： | ￥1080.0 |
|---|---|---|---|
| 规格： | 5ug | 产品价格： | ￥2415.0 |
| 规格： | 50ug | 产品价格： | ￥17000.0 |
CATALOGUE NUMBER
CHM-243
SYNONYMS
INTRODUCTION
Platelet factor-4 is a 70-amino acid protein that is released from the alpha-granules of activated platelets . Its major physiologic role appears to be neutralization of molecules on the endothelial surface of blood vessels, thereby inhibiting local antithrombin III activity and promoting coagulation. As a strong chemoattractant for neutrophils and fibroblasts, PF4 probably has a role in inflammation and wound repair. Oncostatin-A is a member of the CXC chemocinfamily. Human PF4 is used for the proof of induced thrombocytopenia. Furthermore it is used as an inhibitor in the angiogenesis during tumor therapy.
DESCRIPTION
The CXCL4 Variant-1 is fused to 6xHis tag at N-Terminus and purified by standard chromatography techniques.
SOURCE
PHYSICAL APPEARANCE
FORMULATION
SOLUBILITY
STABILITY
Please prevent freeze-thaw cycles.
PURITY
AMINO ACID SEQUENCE
SAFETY DATA SHEET
SDS
USAGE
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验CXCL4 Variant-1 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 77 amino acids and having a molecular mass of 8.7 kDa.
The CXCL4 Variant-1 is fused to 6xHis tag at N-Terminus and purified by standard chromatography techniques.
Human Plasma Platelet-Activating Factor Acetylhydrolase
The human plasma platelet-activating factor acetylhydrolase (PAF acetylhydrolase, l-alkyl-2-acetyl-glycerophosphocholine esterase, l-alkyl-2-acetyl- sn -glycero-3-phosphocholine acetohydrolase, EC 3.1.1.47) is a phospholipase A 2 activity
Secretion of Recombinant Human Insulin-Like Growth Factor I (IGF-I)
The development of efficient recombinant protein production processes can be a critical factor in whether or not a pharmaceutical therapeutic protein can enter human clinical trials and ultimately the marketplace. This is especially true
the intracellular mechanisms required for hESC maintenance. This chapter describes the serum-free maintenance of hESC in culture by addition of sphingosine-1-phosphate (S1P) and platelet-derived growth factor (PDGF). This complete protocol provides a chemically
技术资料